Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026.

As of June 30, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled approximately US$9.5 million, an increase from US$4.1 million as of December 31, 2025. Assuming the current cash burn rate for the first half of 2026, management confirms that current liquidity is sufficient to fund planned operations to at least October 2027.